CCL2 and prostate carcinoma: Thus, with our results, new treatment options for UC targeting the interaction between UC and TME cells are emerging, as it has already been demonstrated that small-molecule inhibitors targeting CCL-2 as Bindarit inhibit tumor progression and metastasis in a breast cancer cell line and in prostate cancer xenograft mice (101).